Molecular basis of the mucosal immune system: From fundamental concepts to advances in liposome-based vaccines

Nanomedicine

Volumn 5, Issue 10, 2010, Pages 1617-1640

  Tiwari, Shailja ^a   Agrawal, Govind P ^a   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

IgA; immunity; ligand; liposomes; mucosally associated lymphoid tissue

Indexed keywords

ANTHRAX VACCINE; BOTULINUM TOXIN; CAF 01; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; CPG OLIGODEOXYNUCLEOTIDE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; DIPHTHERIA VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT LABILE TOXIN; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INTERLEUKIN 2; LIPOSOME; MEASLES VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; SALMONELLOSIS VACCINE; TETANUS TOXOID; TRIPLE VACCINE; ULEX EUROPAEUS AGGLUTININ; ULEX EUROPAEUS AGGLUTININ 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; BINDING AFFINITY; BOTULISM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; CHEMICAL MODIFICATION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DENDRITIC CELL; DIARRHEA; DIPHTHERIA; DRUG CONJUGATION; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; FACIAL NERVE PARALYSIS; GIARDIASIS; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LIGAND BINDING; LIPOSOMAL DELIVERY; LYMPHOCYTE FUNCTION; LYMPHOID CELL; LYMPHOID TISSUE; MOLECULAR INTERACTION; MOLECULAR MIMICRY; MUCOSAL IMMUNITY; NANOENCAPSULATION; NANOTECHNOLOGY; NEUROTOXICITY; NONHUMAN; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW; RHINORRHEA; SIGNAL TRANSDUCTION; TARGET CELL; TETANUS; TH1 CELL; TH17 CELL;

ANIMALS; HUMANS; IMMUNITY, MUCOSAL; LIPOSOMES; NANOMEDICINE; NANOTECHNOLOGY; VACCINES;

EID: 78650544598     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.128     Document Type: Review

References (188)

1. Centers for Disease Control and Prevention (CDC): Deaths and hospitalizations related to 2009 pandemic influenza A (H1N1). Greece, May 2009-February 2010. Morb. Mortal. Wkly Rep. 59(22), 682-686 (2010).
2. Phillips-Quagliata JM, Lamm ME: Migration of lymphocytes in the mucosal immune system. In: Migration and homing of lymphoid cells Boca Raton. Husband AJ (Ed.). CRC Press, Boca Raton, FL, USA, 53-75(1988).
3. Hamann A, Andrew DP, Jablonski Westrich D, Holz-mann B, Butcher EC: Role of a4 integrins in lymphocyte homing to mucosal tissues in vivo. J. Immunol. 152, 3282-3293 (1994). (Pubitemid 2079555)
4. McGhee JR, Lamm ME, Strober W: Mucosal immune responses: an overview. Mucosal Immunol. (2nd Edition). Academic Press, New York, USA 485-506 (1999).
5. Ogra PL, Faden H, Welliver RC: Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14(2), 430-445 (2001). (Pubitemid 32294678)
6. Nugent J, Po AL, Scott EM: Design and delivery of non-parenteral vaccines. J. Clin. Pharm. Ther. 23(4), 257-285 (1998). (Pubitemid 28532450)
7. Nilsen E, Lundin K, Krajd R, Scott H, Soihd LM, Brandtzaeg R: Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytoldnes with Th1 or ThO profile dominated by interferon-g. Gut 37, 766-776 (1995).
8. Brandtzaeg P, Kiyono H, Pabst R, Russell MW: Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol. 1(1), 31-37 (2008).
9. Keljo DJ, Hamilton JR: Quantitative determination of macromolecular transport rate across intestinal Peyers patches. Am. J. Physiol. 244, G637-G644 (1983).
10. Rescigno M, Urbano M, Valzasina B et al.: Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2, 361-367 (2001). (Pubitemid 33706348)
11. Malik B, Goyal AK, Mangal S, Zakir F, Vyas SP: Implication of gut immunology in the design of oral vaccines. Curr. Mol. Med. 10(1), 47-70 (2010).
12. Chadwick S, Kriegel C, Amiji M: Nanotechnology solutions for mucosal immunization. Adv. Drug Deliv. Rev. 62, 394-407 (2010).
13. Holmgren J, Czerkinsky C: Mucosal immunity and vaccines. Nat. Med. Suppl. 11(4), S45-S53 (2005). (Pubitemid 40562303)
14. Kiyono H, Fukuyama S: NALT versus Peyers-patch mediated mucosal immunity. Nat. Rev. Immunol. 4, 699-710 (2004).
15. Gebert A, Rothktter HJ, Pabst R: M cells in Peyers patches of the intestine. Int. Rev. Cytol. 167, 91-159 (1996).
16. Tyrer P, Foxwell AR, Cripps AW, Apicella MA, Kyd JM: Microbial pattern recognition receptors mediate M-cell uptake of a Gram-negative bacterium. Infect. Immun. 74(1), 625-631 (2006). (Pubitemid 43023118)
17. Gulberg E, Keita AV, Salim KS et al.: Identification of cell adhesion molecules in the human follicle-associated epithelium that improve nanoparticle uptake into the Peyers patches. J. Pharmacol. Exp. Ther. 319, 632-639 (2006).
18. Kraehenbuhl JP, Neutra MR: Epithelial M cells: differentiation and function. Annu. Rev. Cell Dev. Biol. 16, 301-332 (2000).
19. Secott TE, Lin TL, Wu CC: Mycobacterium avium subsp. paratuberculosis fibronectin attachment protein facilitates M-cell targeting and invasion through a fibronectin bridge with host integrins. Infect. Immun. 72, 3724-3732 (2004). (Pubitemid 38828214)
20. Tyrer P, Foxwell AR, Kyd JM, Harvey M, Sizer P, Cripps AW: Validation and quantitation of an in vitro M cell model. Biochem. Biophys. Res. Commun. 299, 377-383 (2002). (Pubitemid 35365638)
21. Clark MA, Jepson NL, Simmons T, Booth A, Hirst BH: Differential expression of lectin-binding sites defines mouse intestinal M-cells. J. Histochem. Cytochem. 41, 1679-1687 (1993).
22. Giannasca PJ, Giannasca KT, Leichtner AM, Neutra MR: Regional differences in glycoconjugates of intestinal M cells in mice: potential targets for mucosal vaccines. Am. J. Physiol. 267, G1108-G1121 (1994).
23. Chionh YT, Wee JLK, Every AL, Ng GZ, Sutton P: M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens. Infect. Immun. 77(7), 2962-2970 (2009).
24. Lavelle EC: Lectins and microparticles for enhanced oral vaccination. Methods 38, 84-89 (2006).
25. Mantis NJ, Cheung MC, Chintalacharuvu KR, Rey J, Corthsy B, Neutra MR: Selective adherence of IgA to murine Peyers patch M cells: evidence for a novel IgA receptor. J. Immunol. 169, 1844-1851 (2002). (Pubitemid 34857646)
26. Smith MW, Thomas NW, Jenkins PG, Miller NGA, Cremaschi D, Porta C: Selective transport of microparticles across Peyers patch follicle-associated M cells from mice and rats. Exp. Physiol. 80, 735-743 (1995).
27. Blanco LP, DiRita VJ: Antibodies enhance interaction of Vibrio cholerae with intestinal M-like cells. Infect. Immun. 74(12), 6957-6964 (2006). (Pubitemid 44913171)
28. Clark MA, Hirst BH: Expression of junction-associated proteins differentiates mouse intestinal M cells from enterocytes. Histochem. Cell Biol. 118, 137-147 (2002). (Pubitemid 34983971)
29. Gebert A, Bartels H: Occluding junctions in the epithelia of the gut-associated lymphoid tissue (GALT) of the rabbit ileum and caecum. Cell Tissue Res. 266, 301-314 (1991).
30. Brayden DJ, Baird AW: A distinctive electrophysiological signature from the Peyers patches of rabbit intestine. Br. J. Pharmacol. 113, 593-599 (1994).
31. Mantis NJ, Frey A, Neutra MR: Accessibility of glycolipid and oligosaccharide epitopes on rabbit villous and follicle-associated epithelium. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G915-G923 (2000). (Pubitemid 30439170)
32. Bhalla DK, Owen RL: Cell renewal and migration in lymphoid follicles of Peyers patches and cecum - an autoradiographic study in mice. Gastroenterology 82, 232-242 (1982).
33. Niess JH, Brand S, Gu X et al.: CX3CR1- mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 307, 254-258 (2005). (Pubitemid 40116240)
34. Pamer EG: Immune responses to commensal and environmental microbes. Nat. Immunol. 8, 1173-1178 (2007). (Pubitemid 350011753)
35. Macpherson AJ, Uhr T: Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 303, 1662-1665 (2004). (Pubitemid 38338323)
36. Mohamadzadeh M, Olson S, Kalina WV et al.: Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc. Natl Acad. Sci. USA 102, 2880-2885 (2005). (Pubitemid 40299885)
37. Mohamadzadeha M, Duongb T, Sandwickd SJ, Hooverd T, Klaenhammer TR: Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc. Natl Acad. Sci. USA 17(106) 4331-4336 (2009).
38. Beaty SR, Rose CE Jr, Sung SS: Diverse and potent chemokine production by lung CD11bhigh dendritic cells in homeostasis and in allergic lung inflammation. J. Immunol. 178, 1882-1895 (2007).
39. Kim TS, Braciale TJ: Respiratory dendritic cell subsets differ in their capacity to support the induction of virus-specific cytotoxic CD8+ T cell responses. PLoS One 4 (1), E4204 (2009).
40. Rescigno M, Sabatino AD: Dendritic cells in intestinal homeostasis and disease. J. Clin. Invest. 119(9), 2441-2450 (2009).
41. Novak N, Allam JP, Betten H, Haberstok J, Bieber T: The role of antigen presenting cells at distinct anatomic sites: they accelerate and they slow down allergies. Allergy 59, 5-14 (2004). (Pubitemid 38167945)
42. Seder RA, Darrah PA: T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247-258 (2008).
43. Bland PW, Warren LG: Antigen presentation by epithelial cells of rat small intestine. II. Selective induction of suppressor T cells. Immunology 58, 9-14 (1986). (Pubitemid 16120924)
44. Mayer L, Shlien R: Evidence for function of la molecules on gut epithelial cells in man. J. Exp. Med. 166, 1471-1483 (1987). (Pubitemid 18051437)
45. Farstad IN, Halstensen TS, Lien B, Kilshaw PJ, Lazarovitz A, Brandtzaeg P: Distribution of p7 integrins in human intestinal mucosa and organized gut-associated lymphoid tissue. Immunology 89, 227-237 (1996). (Pubitemid 26340127)
46. Wong PY, Yue G, Yin K: Mucosal addressin cell adhesion molecule-1. A structural and functional analysis demarcates the integrin hinding motif. J. Immunol. 157, 2488-2497 (1996).
47. McDermott MR, Bienenstock J: Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J. Immunol. 122, 1892-1898 (1979). (Pubitemid 9175317)
48. Brandtzaeg P: Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25, 5467-5484 (2007). (Pubitemid 47031365)
49. Macpherson AJ, Geuking MB, McCoy KD: Immune responses that adapt the intestinal mucosa to commensal intestinal bacteria. Immunology 115,153-162 (2005). (Pubitemid 40733400)
50. Roy MJ, Varvayanis M: Development of dome epithelium in gut associated lymphoid tissues: association of IgA with M cells. Cell Tissue Res. 248, 645-651 (1987).
51. Mantis NJ, Cheung MC, Chintalacharuvu KR, Re J, Corthsy B, Neutra MR: Selective adherence of IgA to murine Peyers patch M cells: evidence for a novel IgA receptor. J. Immunol. 169, 1844-1851 (2002).
52. Phalipon A, Corthesy B: Novel functions of the polymeric Ig receptor: well beyond transport of immunoglobulins. Trends Immunol. 24, 55-58 (2003). (Pubitemid 36120638)
53. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB: Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 272, 104-107 (1996). (Pubitemid 26110760)
54. Bomsel M, Heyman M, Hocini H, Lagaye S, Belec L, Dupont C: Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 9, 277-287 (1998). (Pubitemid 28400041)
55. Fujioka H, Emancipator SN, Aikawa M, Huang DS, Blatnik F, Karban T: Immunocytochemical colocalization of specific immunoglobulin A with Sendai virus protein in infected polarized epithelium. J. Exp. Med. 188, 1223-1229 (1998). (Pubitemid 28478010)
56. Mazanec MB, Coudret CL, Fletcher DR: Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J. Virol. 69, 1339-1343 (1995).
57. Robinson JK, Blanchard TG, Levine AD, Emancipator SN, Lamm ME: A mucosal IgA-mediated excretory immune system in vivo. J. Immunol. 166, 3688-3692 (2001).
58. Offit PA, Cunningham SL, Dudzik KI: Memory and distribution of virus-specific cytotoxic T lymphocytes (CTLs) and CTL precursors after rotavirus infection. J. Virol. 65, 1318-1324 (1991).
59. Hou S, Doherty PC: Partitioning of responder CD8+ T cells in lymph node and lung of mice with Sendai virus pneumonia by LECAM-1 and CD45RB phenotype. J. Immunol. 150(5), 494-500 (1993). (Pubitemid 23180663)
60. Issekutz TB: The response of gut-associated T lymphocytes to intestinal viral immunization. J. Immunol. 133, 2955-2959 (1984).
61. Offit PA, Dudzik KI: Rotavirus-specific cytotoxic T lymphocytes appear at the intestinal mucosal surface after rotavirus infection. J. Virol. 63, 3507-3513 (1989).
62. Bailey M, Hail L, Bland PW, Stokes CR: Production of cytokines by lymphocytes front spleen, mesenteric lymph node and intestinal lamina propria of pigs. Immunology 82, 577-583 (1994). (Pubitemid 24263384)
63. Breese E, Braegger CR, Corrigan CJ, Walker-Smith JA, MacDonaid TT: Interieukin-2- and interferon-g-secreting T cells in normal and diseased human intestinal mucosa. Immunology 78, 127-131 (1993). (Pubitemid 23035859)
64. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A: Mucosal immunization and adjuvants: a brief overview of recent advances and challenges. Vaccine 21(Suppl. 2), 589-595 (2003). (Pubitemid 36588654)
65. Ryan EJ, Daly LM, Mills KHG: Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol. 19(8), 293-304 (2001).
66. Neutra MR, Kozlowski PA: Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6, 148-158 (2006).
67. Lemoine D, Francotte M, Preat V: Nasal vaccines from fundamental concepts to vaccine development. Pharma Sci. 8(1), 5-18 (1998). (Pubitemid 28180005)
68. Kemble G, Greenberg H: Novel generations of influenza vaccines. Vaccine 21(16), 1789-1795 (2003). (Pubitemid 36398375)
69. Isaka M, Yasuda Y, Taniguchi T et al.: Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant. Vaccine 21, 1165-1173 (2003). (Pubitemid 36142053)
70. Lewis DJM, Huo Z, Barnett S et al.: Transient facial nerve paralysis (Bells Palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 4(9), E6999 (2009).
71. Mutsch M, Zhou W, Rhodes P et al.: Use of the inactivated intranasal influenza vaccine and the risk of Bells palsy in Switzerland. N. Engl. J. Med. 350(9), 896-903 (2004). (Pubitemid 38252537)
72. Mestecky J, Moldoveanu Z, Michalek SM, Morrow CD, Compans RW, Schafer DP: Current opinions for vaccine delivery systems by mucosal routes. J. Control. Release 48, 243-257 (1997). (Pubitemid 27401982)
73. Jain S, Sharma RK, Vyas SP: Chitosan nanoparticles encapsulated vesicular systems for oral immunization: preparation, in-vitro and in-vivo characterization. J. Pharm. Pharmacol. 58(3) 303-310 (2006). (Pubitemid 43344572)
74. Dea-Ayuela, Iniguez SR, Bolas-Fernandez F: Microcapsules formulated in the enteric coating copolymer Eudragit L100 as delivery systems for oral vaccination against infections by gastrointestinal nematode parasites. J. Drug Target. 14(8), 567-575(2006). (Pubitemid 44592890)
75. Mercier GT, Nehete PN, Passeri MF et al.: Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 25(52), 8687-8701 (2007).
76. Holmgren J, Czerkinsky C: Mucosal immunity and vaccines. Nat. Med. 11, 545-553 (2005). (Pubitemid 40562303)
77. Sakaguchi S, Wing K, Miyara M: Regulatory. T cells-a brief history and perspective. Eur. J. Immunol. 37, S116-S123 (2007). (Pubitemid 350131275)
78. Yuki Y, Kiyono H: New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol. 13(5), 293-310 (2003). (Pubitemid 37082192)
79. Neurath MF, Finotto S, Glimcher LH: The role of Th1/Th2 polarization in mucosal immunity. Nat. Med. 8 (6), 567-573 (2002). (Pubitemid 34633433)
80. Ouyang W, Hning ML, Gao Z et al.: Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 12, 27-37 (2000). (Pubitemid 30069212)
81. Krup OC, Kroll I, Bose G, Falkenberg FW: Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome encapsulated IL-2 as a depot formulation. J. Immunother. 22(6), 525-538 (1999). (Pubitemid 29526348)
82. McKeever U, Barman S, Hao T et al.: Protective immune responses elicited in mice by immunization with formulations of poly(lactideco-glycolide) microparticles. Vaccine 20(11-12), 1524-1531 (2002). (Pubitemid 34169791)
83. Clark MA, Blair H, Liang L, Brey RN, Brayden D, Hirst BH: Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 20(1-2), 208-217 (2001). (Pubitemid 32905334)
84. Kreuter J, Liehl E: Protection induced by inactivated influenza virus vaccines with polymethylmethacrylate adjuvants. Med. Microbiol. Immunol. (Berl) 165(2), 111-117 (1978). (Pubitemid 8360285)
85. Gregoriadis G: Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 13, 527-537 (1995).
86. Childers NK, Michalek SM: Liposomes, Novel Delivery Systems for Oral Vaccines. OHagan DT (Ed.). CRC Press, Boca Raton, FL, USA (1994).
87. Frezard F: Liposomes: from biophysics to the design of peptide vaccines. Braz. J. Med. Biol. Res. 32(2), 181-189 (1999). (Pubitemid 29098198)
88. Zhou F, Kraehenbuhl JP, Neutra MR: Mucosal IgA response to rectally administered antigen formulated in IgA coated liposomes. Vaccine 13(7), 637-644 (1995).
89. Tomizawa H, Aramaki Y, Fujii Y et al.: Uptake of phosphatidylserine liposomes by rat Peyers patches following intraluminal administration. Pharm. Res. 10(4), 549-552 (1993). (Pubitemid 23113046)
90. Fujii Y, Aramaki Y, Hara T, Yachi K, Kikuchiand H, Tsuchiya S: Enhancement of systemic and mucosal immune responses following oral administration of liposomes. Immunol. Lett. 36, 65-70 (1993). (Pubitemid 23166296)
91. Shek PN, Yung YK, Stanacev Z: Comparison between multilameliar and unilameliar liposomes in enhancing antibody formation. Immunology 49, 37-44 (1983).
92. Tseng LP, Chiou CJ, Chen CC et al.: Effect of lipopolysaccharide on intranasal administration of liposomal Newcastle disease virus vaccine to SPF chickens. Vet. Immunol. Immunopathol. 131, 285-289 (2009).
93. Amin M, Jaafari MR, Tafaghodi M: Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. Colloids Surfs B: Biointerfaces 74, 225-229 (2009).
94. Owen RL: Sequential uptake of horseradish peroxidase by lymphoid follicle epithelium of Peyers patches in the normal unobstructed mouse intestine: an ultrastructural study. Gastroenterology 72, 440-451 (1977).
95. Rosen LV, Podjaski B, Bettman I, Otto HF: Observations on the ultrastructure and function of the so-called microfold or membranous cells (M cells) by means of peroxidase as a tracer. Virchows Arch. A. Pathol. Anat. Histol. 390, 289-212 (1981).
96. Gould-Fogerite S, Edghill-Smith Y, Kheiri M et al.: Lipid matrix-based subunit vaccines: a structure-function approach to oral and parenteral immunization. AIDS Res. Hum. Retroviruses 10(Suppl. 2), S99-S103 (1994). (Pubitemid 24375447)
97. Jain S, Singh P, Mishra V, Vyas SP: Mannosylated niosomes as as adjuvant-carrier system for oral genetic immunization against hepatitis B. Immunol. Lett. 101, 41-49 (2005). (Pubitemid 41297497)
98. Smith DC, Lord JM, Roberts LM, Johannes L: Glycosphingolipids as toxin receptors. Semin. Cell Dev. Biol. 15, 397-408 (2004). (Pubitemid 38781902)
99. Kataoka K, McGhee JR, Kobayashi R, Fujihashi K, Shizukuishi S, Fujihashi K: Nasal Flt3 ligand cDNA elicits CD11c+CD8+ dendritic cells for enhanced mucosal immunity. J. Immunol. 172(6), 3612-3619 (2004).
100. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor a. J. Exp. Med. 179, 1109-1118 (1994). (Pubitemid 24091769)
101. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B: DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J. Exp. Med. 189, 169-178 (1999). (Pubitemid 29047036)
102. Sallusto F, Cella M, Danieli C, Lanzavecchia A: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182, 389-400 (1995).
103. Chang JS, Choi MJ: pH-Sensitive liposomes as adjuvants for peptide antigens. Methods Enzymol. 373, 127-136 (2003).
104. Lee KY, Chun E, Seong BL: Investigation of antigen delivery route in vivo and immune-boosting effects mediated by pH-sensitive liposomes encapsulated with Kb-restricted CTL epitope. Biochem. Biophys. Res. Commun. 292, 682-688 (2002). (Pubitemid 34681113)
105. Haan A, Geerligs HJ, Huchshorn JP, Scharrenburg GJM, Palache AM, Wilsch J: Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 13(2) 15-162 (1995).
106. Haan A, Tomee JFC, Huchshornj JP, Wilschut J: Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. Vaccine 13(14), 1320-1324 (1995).
107. Gregoriadis G, Saffie R, Souza JB: Liposome-mediated DNA vaccination. FEBS Lett. 402,107-110 (1997). (Pubitemid 27078239)
108. Meyer KB, Thompson M, Levy M, Barron L, Szoka FJ: Intratracheal gene delivery to the mouse airway characterization of plasmid DNA expression and pharmacokinetics. Gene Ther. 2, 450-460 (1995).
109. Felgner PL, Tsai YJ, Sukhu L et al.: Improved cationic lipid formulation for in vivo gene therapy. Ann. NY Acad. Sci. 772, 126-139 (1996). (Pubitemid 26078772)
110. Khatri K, Goyal AK, Gupta PN, Mishra N, Mehta A, Vyas SP: Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 26, 2225-2233 (2008).
111. Wang D, Christopher ME, Nagata LP et al.: Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses J. Clin. Virol. 315, 599-5106 (2004). (Pubitemid 39574715)
112. Guidotti LG, Ando K, Hobbs MV et al.: Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl. Acad. Sci. USA 91, 3764-3768 (1994). (Pubitemid 24139512)
113. Vogel FR: Adjuvants in perspective. Dev. Biol. Stand. 92, 241-248 (1998).
114. Okada E, Sasaki S, Ishii N et al.: Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J. Immunol. 159(7), 3638-3647 (1997). (Pubitemid 127482124)
115. Wang D, Xu J, Feng Y et al.: Liposomal oral DNA vaccine (mycobacterium DNA) elicits immune response. Vaccine 28, 3134-3142 (2010).
116. Okada J, Cohen S, Langer R: In vitro evaluation of polymerized liposomes as an oral drug delivery system. Pharm. Res. 12, 576-582 (1995). (Pubitemid 26156932)
117. Chen H, Torchilin V, Langer R: Polymerized liposomes as potential oral vaccine carriers: stability and bioavailability. J. Control. Release, 42, 263-272 (1996). (Pubitemid 26338601)
118. Kunisawa J, Nakanishi T, Takahashi I et al.: Sendai virus fusion protein-mediates simultaneous induction of MHC class I/II-dependent mucosal and systemic immune responses via the nasopharyngeal-associated lymphoreticular tissue immune system. J. Immunol. 167, 1406-1412 (2001). (Pubitemid 32703138)
119. Nakanishi T, Hayashi A, Kunisawa J et al.: Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur. J. Immunol. 30, 1740-1747 (2000). (Pubitemid 30342818)
120. Hayashi A, Nakanishi T, Kunisawa J et al.: A novel vaccine delivery system using immuno potentiating fusogenic liposomes. Biochem. Biophys. Res. Commun. 261, 824-828 (1999). (Pubitemid 29408141)
121. Takata S, Ohtani O, Watanabe Y: Lectin binding patterns in rat nasal-associated lymphoid tissue (NALT) and the in fluence of various types of lectin on particle uptake in NALT. Arch. Histol. Cytol. 63, 305-312 (2000).
122. Jeong KI, Suzuki H, Nakayama H, Doi K: Ultrastructural study on the follicle-associated epithelium of nasal-associ ated lymphoid tissue in specific pathogen-free (SPF) and conventional environment-adapted (SPF-CV) rats, J. Anat. 196, 443-451(2000). (Pubitemid 30333064)
123. Kunisawa J, Nakagawa S, Mayumi T: Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development. Adv. Drug Deliv. Rev. 52, 177-186 (2001). (Pubitemid 33097544)
124. Yuba E, Kojima C, Harada A, Tana, Watarai S, Kono K: pH-Sensitive fusogenic polymer-modified liposomes as a carrier of antigenic proteins for activation of cellular immunity. Biomaterials 31, 943-951 (2010).
125. Davidsen J, Rosenkrands I, Christensen D et al.: Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses. Biochim. Biophys. Acta 1718, 22-31 (2005). (Pubitemid 41698893)
126. Christensen D, Foged C, Rosenkrands I et al.: CAF01 liposomes as a mucosal vaccine adjuvant: in vitro and in vivo investigations. Int. J.Pharm. 390, 19-24 (2010).
127. Van Uden J, Raz E: Introduction to immunostimulatory DNA sequences. Springer Semin. Immunopathol. 22, 1-9 (2000).
128. Pisetsky DS: Mechanisms of immune stimulation by bacterial DNA. Springer Semin. Immunopathol. 22, 21-33 (2000).
129. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM: CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl Acad. Sci. USA 93, 2879-2883 (1996). (Pubitemid 26116242)
130. Ballas ZK, Rasmussen WL, Krieg AM: Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157, 1840-1845 (1996).
131. Lipford GB, Sparwasser T, Bauer M, Zimmermann S, Koch ES, Heeg K: Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol. 27, 3420-3426 (1997). (Pubitemid 28018040)
132. Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW: Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28, 2045-2054 (1998). (Pubitemid 28271721)
133. Heeg K, Zimmermann S: CpG DNA as a Th1 trigger. Int. Arch Allergy Immunol. 121, 87-97 (2000). (Pubitemid 30130780)
134. McCluskie MJ, Chu Y, Xia JL, Jessee J, Gebyehu G, Davis HL: Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA. Antisense Nucleic Acid Drug Dev. 8, 401-414 (1998). (Pubitemid 28510826)
135. Joseph A, Louria-Hayon I, Plis-Finaro A et al.: Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 20, 3342-3354 (2002). (Pubitemid 35245818)
136. Nohria A, Rubin RH: Cytokines as potential vaccine adjuvants. Biotherapy 7, 261-269 (1994). (Pubitemid 24324510)
137. Kim TS, DeKruyff RH, Rupper R, Maecker HT, Levy S, Umetsu DT: An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J. Immunol.158, 4137-4144 (1997). (Pubitemid 127483912)
138. Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedara E: A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/ neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Vaccine 17, 1223-1238 (1999). (Pubitemid 29132958)
139. Oya Alpar H, Somavarapu S, Atuah KN, Bramwell VW: Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug Deliv. Rev. 57, 411-430 (2005). (Pubitemid 39550968)
140. Chiou C, Tseng LP, Deng MC et al.: Mucoadhesive liposomes for intranasal immunization with an avian influenza virus vaccine in chickens. Biomaterials 30, 5862-5868 (2009).
141. Tiwari S, Goyal AK, Mishra N et al.: Liposome in situ gelling system: novel carrier based vaccine adjuvant for intranasal delivery of recombinant protein vaccine. Procedia Vaccinol. 1, 148-163 (2009).
142. Tam JP, Spetzler JC: Chemoselective approaches to the preparation of peptide dendrimers and branched artificial proteins using unprotected peptides as building blocks. Biomed. Pept. Proteins Nucleic Acids. 1, 123-132 (1995).
143. Fostera N, Hirst BH: Exploiting receptor biology for oral vaccination with biodegradable particulates. Adv. Drug Deliv. Rev. 57, 431-450 (2005).
144. Gupta PN, Vyas SP: Investigation of lectinized liposomes as M-cell targeted carrier adjuvant for mucosal immunization. Colloids and Surf. B: Biointerfaces 82(1), 118-125 (2011).
145. Pappo J, Ermak TH, Steger HJ: Monoclonal antibody directed targeting of fluorescent polystyrene microsphere to Peyers patches. Immunology 73, 277-280 (1991).
146. Velez CN, Tonkonogy SL, Lichtman SN, Cho MJ: Sensitized liposomes as an antigen delivery system for the stimulation of mucosal immunity. J. Drug Target 5(1), 15-24 (1997).
147. Lian T, Bui T, Ho RJY: Formulation of HIV-envelope protein with lipid vesicles expressing ganglioside GM1 associated to cholera toxin B enhances mucosal immune responses. Vaccine 18, 604-611 (2000). (Pubitemid 29509843)
148. Harokopakis E, Hajishengallis G, Michalek SM: Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system. Infect. Immun. 66(9), 4299-4304 (1998). (Pubitemid 28402705)
149. Salazar-Gonzalez RM, Niess JH, Zammit DJ et al.: CCR6-mediated dendritic cell activation of pathogen-specific T cells in Peyers patches. Immunity 24, 623-632 (2006). (Pubitemid 43744358)
150. Iwasaki A and Kelsall BL: Unique functions of CD11B+ CD8a+ and double-negative Peyers patch dendritic cells. J. Immunol. 166, 4884-4890(2001)
151. Tezuka H, Abe Y, Iwata M et al.: Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells. Nature 448, 929-933 (2007). (Pubitemid 47312771)
152. Contractor N, Louten J, Kim L, Biron CA, Kelsall BL: Cutting edge: Peyers patch plasmacytoid dendritic cells (pDCs) produce low levels of type I interferons: possible role for IL-10, TGFb, and prostaglandin E2 in conditioning a unique mucosal pDC phenotype. J. Immunol. 179, 2690-2694 (2007).
153. Coombes JL, Siddiqui KRR, Arancibia- Carcamo CV et al.: A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-b and retinoic acid dependent mechanism. J. Exp. Med. 204, 1757-1764 (2007).
154. Denning TL, Wang YC, Patel SR, Williams IR, Pulendran B: Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat. Immunol. 8, 1086-1094 (2007). (Pubitemid 47423756)
155. Uematsu S, Fujimoto K, Jang MH et al.: Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat. Immunol. 9, 769-776 (2008). (Pubitemid 351859160)
156. Johansson-Lindbom B, Agace WW, Parker CM, Powrie F: Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J. Exp. Med. 202, 1063-1073 (2005). (Pubitemid 41464500)
157. Broere F, Pre MF, Berkel LA, Garssen J et al.: Cyclooxygenase-2 in mucosal DC mediates induction of regulatory T cells in the intestine through suppression of IL-4. Mucosal Immunol. 2, 254-264 (2009).
158. Godthelp T, Fokkens WJ, Kleinjan A et al.: Antigen presenting cells in the nasal mucosa of patients with allergic rhinitis during allergen provocation. Clin. Exp. Allergy 26, 677-688 (1996). (Pubitemid 26226582)
159. Munn DH, Sharma MD, Lee JR et al.: Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297, 1867-1870 (2002).
160. Novak N, Haberstok J, Geiger E, Bieber T: Dendritic cells in allergy. Allergy 54, 792-803 (1999). (Pubitemid 29402161)
161. Bertorelli G, Bocchino V, Zhou X et al.: Dendritic cell number is related to IL-4 expression in the airways of atopic asthmatic subjects. Allergy 55, 449-454 (2000). (Pubitemid 30230354)
162. Akbari O, DeKruyff RH, Umetsu DT: Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. 2, 725-731 (2001). (Pubitemid 32747162)
163. Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B: TGFb in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17- producing T cells. Immunity 24, 179-189 (2006). (Pubitemid 43214587)
164. Mangan PR, Harrington LE, OQuinn DB et al.: Transforming growth factor-b induces development of the TH17 lineage. Nature 441, 231-234 (2006).
165. Bettelli E, Carrier Y, Gao W et al.: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
166. Martin-Orozco N, Muranski P, Chung Y et al.: T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31(20), 787-798 (2009).
167. Khader SA, Bell GK, Pearl JK et al.: IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8(4), 369-377 (2007).
168. Jaffar Z, Ferrini ME, Herritt LA, Roberts K: Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA level. J. Immunol. 182, 4507-4511 (2009).
169. Datta SK, Sabet M, Nguyen KPL et al.: Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proc. Natl Acad. Sci. 107(23), 10638-10643 (2010).
170. Yamamoto S, Kiyono H, Yamamoto M, Imaoka K, Fujihashi K, van Ginkel FW: A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl Acad. Sci. USA 94(10), 5267-5272 (1997). (Pubitemid 27214772)
171. Rowe B, Taylor J, Bettelheim KA: An investigation of travellers diarrhoea. Lancet 1(7636), 1-5 (1970).
172. Tamura S, Samegai Y, Kurata H, Nagamine T, Aizawa C, Kurata T: Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 6(5), 409-413 (1998).
173. Hagiwara Y, Kawamura YI, Kataoka K et al.: A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J. Immunol. 177, 3045-3054 (2006). (Pubitemid 44277821)
174. Yoshino N, Fujihashi K, Hagiwara Y et al.: Co-administration of cholera toxin and apple polyphenol extract as a novel and safe mucosal adjuvant strategy. Vaccine 27, 4808-4817 (2009).
175. Romero JF, Ciabattini A, Guillaume P et al.: Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge. Vaccine 27, 1266-1271 (2009).
176. Kende M, Tan X, Wlazlowski C, Williams R, Lindsey C, Giudice GD: Enhancement of intranasal vaccination with recombinant chain A ricin vaccine (rRV) in mice by the mucosal adjuvants LTK63 and LTR72. Vaccine 25, 3219-3227 (2007). (Pubitemid 46482754)
177. Tempesta M, Cameroa M, Bellacicco AL et al.: Caprine herpesvirus 1 vaccine with the LTK63 mutant as a mucosal adjuvant induces strong protection against genital infection in goats. Vaccine 25, 7927-7930 (2007). (Pubitemid 350011000)
178. Isaka M, Yasuda Y, Taniguchi T et al.: Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant. Vaccine 21, 1165-1173 (2003). (Pubitemid 36142053)
179. Klinguer C, Beck A, De-Lys P et al.: Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens. Vaccine 19, 4236-4244 (2001). (Pubitemid 32703645)
180. Abdul-Wahid A, Faubert G: Mucosal delivery of a transmission-blocking DNA vaccine encoding Giardia lamblia CWP2 by Salmonella typhimurium bactofection vehicle. Vaccine 25(50), 8372-8383 (2007). (Pubitemid 350137605)
181. Xu Q, Pichichero ME, Simpson LL, Elias M, Smith LA, Zeng M: An adenoviral vector-based mucosal vaccine is effective in protection against botulism gene-based mucosal vaccine against botulism. Gene Ther. 16, 367-375 (2009).
182. Jakobsen H, Bjarnarson S, Giudice GD, Moreau M, Siegrist CA, Jonsdottir I: Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect. Immun. 70(3), 1443-1452 (2002). (Pubitemid 34163422)
183. Estrada A, McDermott MR, Underdown BJ, Snider DP: Intestinal immunization of mice with antigen conjugated to anti-MHC class II antibodies. Vaccine 13(10), 901-907 (1995).
184. Aguila A, Donachie AM, Peyre M, McSharry CP, Sesardic D, Mowat AM: Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine. Vaccine 24, 5201-5210 (2006). (Pubitemid 43818190)
185. Jepson MA, Clark MA, Foster N et al.: Targeting to intestinal M cells. J. Anat. 189, 507-516 (1996). (Pubitemid 27011003)
186. Clark MA, Jepson MA, Simmons NL, Hirst BH: Expression of junction-associated proteins differentiates mouse intestinal M cells from enterocytes. Tissue Res. 282, 455-461 (1995).
187. Neutra MR, Phillips T, Mayer E, Fishkind DJ, Lazarides E: Intermediate filaments as mechanical integrators of cellular space. Cell Tissue Res. 247, 537-546 (1987).
188. Porta C, James PS, Phillips AD, Savidge TC, Smith MW, Cremaschi D: Particle uptake by Peyers patches: a pathway for drug and vaccine delivery. Exp. Physiol. 77, 929-932 (1992)